REPAIR Impact Fund

The Repair Impact Fund is an investment fund established in 2018 and operated by Novo Holdings A/S. The fund is backed by $165 million by Novo Holdings A/S equivalent of around £119 million and €135 million. The fund is aiming at investing $20-40 million
Name, origin and investment focus
The name (REPAIR Impact Fund) is an abbreviation of "Replenishing and Enabling the Pipeline for Anti-Infective Resistance".
* 2018: Entasis Therapeutics (NASDAQ: ETTX): Boston-based biotech company which develops new kinds of inhibitors targeting multiresistant infections within the group "Pseudomonas Aeruginosa" strains. Investment: $10 million.<ref name=":7" />
* 2018: Procarta Biosystems: UK-based biotech company focusing on the development of treatments for complicated urinary tract infections and intra-abdominal infections. Investment: $1.7 million (€1.5 million).<ref name=":7" />
Administration and management
Key executives for Novo REPAIR Impact Fund:<ref name=":1" />
* Mr. Aleks Engel, PhD - Director <ref name=":1" />
* Mrs. Emmanuelle Coutanceau, Ph.D - Partner <ref name=":1" />
* Mr. Søren Møller, PhD - Managing Partner Novo Seeds<ref name=":1" />

Main Menu

See Also

Main Menu